The August Wellness Index Report, published by Wellness Eternal, focuses on the discipline that determines whether longevity science reaches anyone at all. The science of living longer means little until it reaches real people. Translational longevity is the work of closing that gap, and its leading voices converge this October at the Translational Longevity Summit in Boston, hosted by Boston BioLife and the Healthspan Action Coalition.
The report identifies three signals: cell science moving from proof of concept to real clinical delivery, evidence emerging as the bridge from research to practice, and clinical strategy and systems proving essential to scaling care. Three experts are featured across three vantage points: Dr. Camillo Ricordi (University of Miami), Dr. David Barzilai (Harvard Medical School), and Dr. Suzie Robertson (Matrix Biologics).
Dr. Camillo Ricordi, a professor at the University of Miami, anchors the first signal: translational cell therapy moving from the laboratory into clinical reality. His work exemplifies the shift from bench to bedside, where decades of research in transplantation and cell therapy are now being translated into treatments that can reverse the drivers of disease and aging.
Dr. David Barzilai, a Harvard Medical School lecturer and longevity medicine physician, represents the second signal: evidence as the bridge to practice. He is known for making complex scientific advances accessible and actionable for clinicians, executives, and policymakers. His role as medical editor of Harvard Health Publishing's Pathways to Longevity underscores his commitment to evidence-based medicine.
Dr. Suzie Robertson, a clinical pharmacist and healthcare strategist at Matrix Biologics, embodies the third signal: strategy and systems that scale care. Her nearly two decades of leadership experience across the healthcare continuum highlight the importance of operational rigor in delivering scientific advances safely and consistently.
The summit's hosts, Joseph Krieger of Boston BioLife and Bernard Siegel of the Healthspan Action Coalition, bring complementary expertise. Krieger, with over 25 years in healthcare and life sciences, built Boston BioLife to accelerate the integration of cutting-edge technologies into everyday practice through accredited education and training. Siegel, a patient advocate and founder of the Healthspan Action Coalition, has been a driving force in the regenerative medicine movement, having conceptualized and co-chaired twenty World Stem Cell Summits.
The Translational Longevity Summit runs October 7 to 11 at the Harvard Enterprise Research Campus in Boston. This gathering underscores the urgent need to translate longevity science into real-world applications. As the Wellness Index Report emphasizes, the future of longevity is not just discovered; it is delivered.
The report applies a four-step verification process built on expert nomination, customer and patient feedback, clinical review, and ongoing performance tracking, ensuring that featured innovations meet an integrity-first standard. The full August report is available at wellnessindexreport.com.
